HUNAN FANGSHENG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.23 CNY | -0.41% |
|
+3.47% | +11.59% |
| Apr. 19 | Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 10 | Fangsheng Pharma's Factories Pass GMP Inspection | MT |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +11.59% | 745M | - | ||
| +20.83% | 43.57B | B- | ||
| +20.70% | 22.7B | B+ | ||
| +17.22% | 14.32B | - | ||
| +11.11% | 13.42B | B+ | ||
| +45.91% | 11.83B | B | ||
| -8.84% | 6.98B | B+ | ||
| -0.05% | 6.79B | - | - | |
| -8.87% | 5.73B | - | - | |
| +12.33% | 5.51B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 603998 Stock
- Ratings Hunan Fangsheng Pharmaceutical Co., Ltd.